To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe programme (NSP), and assessed rates of re-infection. 105 HCV RNA positive participants were enrolled prospectively. Participants were recruited from the largest NSP in Dundee over 42 months. 94/105 individuals commenced treatment. Genotype 1 (G1) individuals (n = 37) were treated with peg-interferon+ribavirin+Simepravir/Telaprevir. Genotype 2/3 (G2/3) (n = 57) received peg-interferon+ribavirin. Weekly study visits took place within the NSP. Mean age of participants was 34.0 years (SD 6.9), 71.3% (61/94) were male. One in five (20/94) participants were homeless. 68.1% (64/94) were on OST (opiate substitution therapy) at enrolment; participants injected median 6.5 times/wk. In terms of clinical outcomes, >80% treatment adherence was 71.3% (67/94). There was no difference in SVR-12 rates by genotype: 81.0% (30/37) for G1 and 82.5% (47/55) for G2/3. At 18 months post-treatment, 15/77 participants were reinfected, followed up over 69.8 person-years, yielding a re-infection rate of 21.5/100 person-years (95% CI 13. 00-35.65). This trial demonstrates that HCV treatment can be delivered successfully to the target population of treatment as prevention strategies. We report higher rates of re-infection than existing estimates among PWID.
| INTRODUC TI ON
The global burden of hepatitis C virus (HCV)-related liver disease continues to rise. 1 In 2010, the number of deaths due to HCV was estimated to be 500 000 worldwide. 2 WHO targets are to eliminate HCV by 2030. 3 In Scotland, over 90% of new HCV infections occur among people who inject drugs (PWID). 4 HCV antibody prevalence among PWID is 58%, similar to other European countries. 5, 6 In 2016, 1.76 million of the 71 million people living with HCV worldwide received treatment (~2.48% treatment uptake). 7 Treatment uptake has been historically low among PWID prior to the introduction of new direct-acting antivirals (DAA) treatments. 8 However, there is now good evidence that HCV treatment is safe and effective among PWID. [9] [10] [11] [12] The latest international guidelines 13,14 now recommend treatment for all PWID. However, latest data from Hep-CORE study found 8/25 (32%) of European countries surveyed continue to refuse treatment to PWID.
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Treating active PWID also has the potential to reduce HCV transmission, a concept known as treatment as prevention (TasP).
Modelling data suggest that scaling-up treatment among current PWID with DAAs is critical to reducing HCV prevalence, [16] [17] [18] and is 
newly diagnosed individuals recruited
cost-effective in settings such as the UK with moderate HCV prevalence. 19 Reductions in prevalence are greater when combined with scale-up of harm reduction interventions-opioid substitution therapy (OST) and high coverage Needle and Syringe Programmes (NSP).
20-22
Recent modelling of the Scottish epidemic attributed 55% of the reduction in HCV incidence from 14.2/100 pyrs in 2008 to 5.5/100 in 2015 to national scale-up of harm reduction interventions.
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To date, studies assessing HCV treatment success among PWID have recruited from populations engaged in hepatology or specialist addiction services. 9, 10, 23, 24 These studies define "active injecting drug use" as those who have injected in the last 6 or 12 months, and many require a period of abstinence from injecting drug use (IDU) prior to starting treatment. These are therefore populations of largely stable PWID, at low risk of transmitting HCV. To achieve the greatest reduction in HCV incidence, treatment programmes should target PWID who are most likely to transmit the virus. This is the study population we aimed to recruit.
In this study, we aimed to test whether 100 people who were currently injecting drugs could be recruited and successfully treated for HCV in a NSP. We also assessed rates of re-infection. The secondary aims were to identify factors associated with treatment adherence, re-infection and cure.
| ME THODS

| Study design and cohort recruitment
Eradicate was a prospective observational study conducted at the 
| Data collection
At enrolment (visit 1), participants completed a questionnaire com- 
| Study outcomes and analysis
Three primary outcomes were assessed: (a) successful recruitment 
| EQ5D
The EQ5D-5D-3L is a standardized questionnaire which assesses quality of life (QoL) in five dimensions. It is widely used to measure health states among this population. 28, 29 During analysis, a single summary QoL index value for each participant was derived using country-specific EQ-5D value sets and a known algorithm. 30 These were then compared to latest UK population norms by age and sex. 
| Re-infection rate
The incidence of re-infection is expressed in person-years. Poisson regression assessed factors associated with re-infection rate. These included age, sex, on OST treatment, homelessness, living with other PWID, history of anxiety and depression and injecting frequency. 35, 36 All analysis was performed in STATA.
| RE SULTS
| Recruitment and baseline characteristics
A total of 724 individuals were tested for HCV at the Needle and Syringe Programme (NSP) during study enrolment period (Figure 1 ).
Of these, 145/724 (20.0%) were HCV antibody positive on DBS testing, with 92 positive on PCR RNA testing. Of these newly diagnosed individuals, 69/92 were recruited into the study. 36 individuals already known to be positive from previous testing were also recruited.
This gives a total of 105 individuals were enrolled into the study, with 94 participants ultimately commencing treatment (Figure 1 ). 
| Treatment outcomes
Overall, 82% (77/94) participants achieved SVR-12 (Appendix S2).
There was no difference in SVR12 rates between genotype: 81.0%
(30/37) for G1 and 82.5% (47/57) for G2/3. 71.3% (67/94) individuals achieved ≥80% treatment adherence (Table 3) . Reasons for nonadherence are available for 15/27 participants; eight missed multiple appointments, four were admitted to hospital with injecting-related health problems and advised to stop treatment; two withdrew from treatment due to deteriorating mental health; one died from suspected drug overdose. Of the 64/94 participants on OST at enrolment, the majority, 93.8% (60/64), remained on OST during the treatment period. All participants attended follow-up at 6-month post-treatment. At 18 months, nine participants had been lost to follow-up (Figure 2 ).
In total, eight participants had died by 18-month follow-up. 
| Predictors of treatment adherence and SVR-12
Longer treatment length (24 weeks vs 12/16 weeks) was associated with reduced treatment adherence, OR 0.35 (95% CI 0.13-0.98) (P = 0.047) ( Unadjusted analysis found age <30 years was weakly associated with a higher re-infection rate (vs 30-40 years, P = 0.063) (vs >40 years, P = 0.14). There was no evidence of correlation between other hypothesized factors (Table 4) . Therefore, we did not perform multivariable regression.
| Re-infection rate
| D ISCUSS I ON
| Main findings
We show that it is feasible to recruit people who inject drugs (PWID) from a community-based needle and syringe programme (NSP) onto HCV treatment, and achieve over 80% SVR-12 and impressive treatment adherence (even with older regimens). Re-infection rates, however, in this population were high at 21.5/100 person-years (95% CI 13.00-35.65) at 18-month post-treatment. Mortality rates in our population also were high.
TA B L E 2 Baseline characteristics of study population
| Strengths and limitations
This is the first HCV treatment study, to our knowledge, in which all enrolment, treatment and follow-up took place in the community at a Needle and Syringe Programme (NSP) and that active injecting was an inclusion criteria. This model achieved high levels of HCV testing and treatment uptake among active injectors, with very low loss to follow-up. The study population is unique; at enrolment, all participants had injected within the past week representing a highly active population of injectors.
The study has several limitations. First, it was a small-scale pilot study involving 94 participants, based in one NSP in Dundee. The size of the study meant there was insufficient power to identify independent predictors of adherence, SVR-12 and re-infection. Injecting risk patterns following SVR-12 were unavailable which also limited analysis of predictors of re-infection. Second, recruitment began before the shift in clinical practice from interferon-based treatment to DAAs-though even with older regimens very high rates of SVR-12
were achieved. We expect that higher rates of cure should be possible with more effective, better tolerated DAAs. Third, follow-up positive PCR results were genotyped to distinguish between relapse and re-infection. Gold standard would be sequencing to confirm re-infection.
| Comparison to existing literature and implications
This study reports rates of re-infection following treatment that are significantly higher than existing estimates among PWID. Two meta-analyses estimate a pooled re-infection rate among PWID of 1.77/100 pyrs to 2.4/100 pyrs. 10, 38 Though recent studies report greater re-infection rates among higher risk populations; 4.9/100
person-years among relapsed PWID 39 to 5.7/100 person-years among individuals hospitalized for a drug-related cause. 35 However, all these studies 10, 35, 36, [38] [39] [40] [41] [42] [43] defined "active PWID" as those who have "injected in the past 6-or 12-months"-except Hilsden et al 44 who defined "active" as having injected in the past 3 months, with a reported re-infection rate of 2.8/100 person-years. This is significantly different to our study population, all of whom had injected in the past week and the majority were injecting daily.
In fact, these re-infection rates are closer to latest estimates of HCV incidence among recent injectors (past 6 months) in Scotland at 12.4/100 pyrs (CI 6.8-19.5) in 2015/2016. 45 This has two implications. First, the evidence supports a critical assumption of impact and economic models that there may be no additional behaviour change following HCV treatment (over and above exposure to other interventions) and re-infection rates are similar to HCV incidence in the community. 16, 17, 19 Second, the high HCV incidence and re-infection rates highlight the failure of current coverage and intensity of harm reduction interventions to minimize injecting risk.
This high re-infection rate, along with a significant mortality rate SVR-12 rates are higher than reported rates among PWID for these drugs in the literature. 10, 32 This may be due to several factors.
The study population is on average younger, with lower fibrosis scores and lower initial HCV RNA levels compared to those in existing studies. 10, 32 These are well-described factors associated with higher cures for interferon, ribavirin and first-generation protease inhibitors. Health-related quality of life was low, in keeping with previous studies among HCV+ populations and PWIDs. 28, 46 Overall, treatment adherence was 71.3%, slightly lower than has been reported in literature. 10, 32 However, these data remain impressive considering this is a highly active injecting population with significant rates of homelessness, incarceration and mental health problems.
Weekly nurse-led follow-up visits and use of contingency management may have influenced adherence. The results add to growing evidence that HCV treatment can be successfully provided through community-based models. 9, 10, 23, 24, 44, 47 Our results demonstrate some association between OST and higher rates of adherence. This is consistent with findings from a previous meta-analysis, 32 with implications for the role of addiction treatment alongside HCV care. Shorter treatment duration was associated with improved adherence (12/16-vs 24-weeks) (P = 0.047).
This has important implications for adherence on current DAA treatment regimens which are now only 8-or 12-weeks. Re-infection rate decreased with age (P = 0.063), consistent with existing literature. 36, 39 There was little association between other hypothesized factors and adherence or re-infection.
| CON CLUS ION
PWID were successfully recruited, treated and followed up from a community NSP. However, we also report higher rates of re-infection than many other studies. This demonstrates that we have successfully engaged with and treated a high-risk injecting population who should be targeted as part of any successful treatment as prevention (TasP) strategy. Scaling-up the intensity of harm reduction and HCV treatment provision is needed to minimize re-infection and reduce HCV transmission in the population.
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